Featured Story | By Fraiser Kansteiner Johnson & Johnson scaled back its Darzalex royalty payments to Genmab in the second quarter, just as its new subcutaneous formulation was hitting the market. Genmab owed a portion of those royalties to drug delivery specialist Halozyme for its subQ technology, J&J argued. But Genmab didn't agree—and now it's taking the dispute into arbitration. read more |
| |
|---|
|
Top Stories By Fraiser Kansteiner Takeda joined forces with drug delivery specialist Elektrofi to see whether the biotech’s microparticle technology can enable simpler dosing of its plasma-derived therapies. The Japanese drugmaker has selected plasma therapies as one of its core interests, and subcutaneous delivery would make them easier for patients to use. read more By Angus Liu Roche’s new spinal muscular atrophy offering Evrysdi is already attracting early interest, thanks to its oral dosing, and the Swiss pharma hopes some longer-term data could further build its case. But no one therapy may not be able to dominate the SMA market, one analyst figures. It may be more of a team approach. read more By Fraiser Kansteiner RNA nanoparticles can stretch, but they bounce back to their original shape—a quality that's perfect for targeting cancers, an Ohio State University team figures. Their drug-infused RNA nanoparticles could slip past tumor walls to strike cancer cells directly, and then exit the body swiftly to lessen side effects. read more By Fraiser Kansteiner Bexson Biomedical is working on a subcutaneous ketamine formulation patients could use to manage pain without costly trips to infusion clinics. Now, it's teamed up with Italy's Stevanato Group to pair its drug with a wearable pump. read more By Eric Sagonowsky With a pandemic spreading globally, vaccines have moved to the forefront of the public’s attention—naturally focused on COVID-19 candidates moving at record speeds. But biopharma companies haven’t given up on their other promising programs. These are the top late-stage vaccine prospects in pipelines today. read more By Ben Adams Whilst COVID-19 consumes our minds and the current budgets of the world, cancer will still develop and kill; genetic abnormalities will create rare diseases with no treatment; millions will still die from influenza. This year, we’ve chosen from a diverse range of those fighting COVID, as well as those fighting longer term plagues against our biology. read more |  | Webinar: Gene Therapy Viruses’ Production and Quality Control Thursday, November 12 | 12pm ET / 9am PT Gene therapy has become a one-time treatment method for a complete cure by fixing genomic errors which altered protein functions of normal cells. In this presentation, we report to establish a facility to manufacture GLP grade viruses and to develop the relevant QC assays at Frontage. Our efforts will facilitate the application of this modern cutting edge technology in clinical arena. Register Today! |
Resources Sponsored by: LabVantage Want to leapfrog lengthy LIMS deployments and position your pharmaceutical lab for success? Find out how with LabVantage Solutions. Sponsored by: Blue Matter Consulting Senior executives from 16 biopharma companies share their thoughts on how COVID-19 will change how the industry engages with its customers. Sponsored by: Evidation Health Achieving patient centricity depends on evolving how evidence is generated. Sponsored by: 4G Clinical This white paper addresses the complexity of basket and umbrella designs, and how modern technology is critical to run flexible, agile and quality-driven trials. Sponsored by: EVERSANA How independent drug launch and commercialization can lead to higher market capitalization. Sponsored by: AMRI Download our white paper to learn more about the growth trends, complex anatomy and intricacies of developing these armed antibodies, as well as AMRI’s approach to their discovery and development. Sponsored by: LexisNexis Risk Solutions Avoid severe compliance penalties by staying on top of evolving laws. Sponsored by: Quotient Sciences This white paper will discuss four principal CMC challenges for the developers of orphan drugs, and the potential solutions which are emerging. Download now >> Sponsored by: Clarify Health In 2020, QED Therapeutics launched first-in-class infigratinib for cholangiocarcinoma (CCA). Learn how the launch team precisely identified and characterized eligible patients by taking an evidence-based approach to its commercial strategy. Sponsored by: Benchling Life science R&D generates a LOT of data. Learn how to make sense of it and harness its potential with this step-by-step guide. Sponsored by: Thermo Fisher Scientific Don’t oversimplify your solubility challenges. Sponsored by: Clinical Ink Download this free whitepaper to learn how to execute fast, high-quality clinical trials through eSource for studies that boost efficiency for both sponsors and sites. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. Sponsored by: PRA Health Sciences Drug developers and stakeholders must find ways to collaborate, rather than compete, as the RACE Act prompts the need for more pediatric research. Sponsored by: Thermo Fisher Scientific Download the whitepaper to learn more. Sponsored by: LexisNexis Risk Solutions Traditionally, pharma companies use a combination of prescription data & internal sales reports to look for potential buyers. Such practice provides only a LIMITED VIEW without competitor information. Download the whitepaper by Optum to see how novel data platforms can uncover hidden insights on medication adherence helping life sciences companies maximize product utilization. Download the whitepaper by Optum to see how novel data platforms can uncover hidden insights on medication adherence helping life sciences companies maximize product utilization. Sponsored by: Catalent Pharmaceutical and biotech companies are spending years developing drugs or promising new biologics, all with the hopes of saving or enhancing patients’ lives. It’s a “race to the finish” in some cases, and the quicker a company can get its product to patients, the better. Sponsored by: Cardinal Health 3PL Services Identifying opportunities to simplify channel strategies and business processes for biopharma companies, their customers and patients. Sponsored by: Paysign Download the whitepaper for a solution designed to connect manufacturers, pharmacists, and patients. In this special guide, you will learn not just about the law but about the portal platform designed to change the entire process for all. Sponsored by: Catalent In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management. Sponsored by: Phlow Corp. Interested in putting patients, people, and planet over profit in a fast-paced environment? Please Apply: VP of Integrated Supply Chain and VP of Manufacturing, Science, & Technology Sponsored by: InterSystems Accurate, timely insights are everything. Whatever the question, the answers demand real world data you can trust. Healthy data advances reliable insights, and takes the error out of AI. Healthy data is not just useable, but invaluable. Healthy data starts with InterSystems. | 
